Drugmaker Biocon said on Wednesday, 18 November, that the European Commission has granted marketing authorisation to Pebrilzo, its biosimilar version of the cancer drug pertuzumab, for treating HER2-positive breast cancer at several stages of the disease across the European Union.
The company said Pebrilzo is the first biosimilar to be cleared by the Commission under the European Medicines Agency's (EMA) new "tailored clinical approach", a lighter evidence route that does not usually require a head-to-head efficacy trial. The decision follows a positive opinion from the EMA's medicines committee, the CHMP, in September.
What the approval covers
According to Biocon's filing, the product has been cleared as a 420 mg concentrate for solution for infusion. The approved uses are:
- alongside trastuzumab and chemotherapy before surgery (neoadjuvant treatment) in adults with HER2-positive breast cancer that is locally advanced, inflammatory or early-stage and carries a high risk of returning;
- after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer at high risk of recurrence;
- with trastuzumab and docetaxel in adults whose HER2-positive cancer has spread or come back in a form that cannot be operated on, and who have not yet received anti-HER2 therapy or chemotherapy for metastatic disease.
Pertuzumab is a monoclonal antibody that latches on to the HER2 protein and blocks the growth of tumour cells that carry too much of it. Biocon said its version was shown to be highly similar to the reference medicine, Perjeta, through extensive laboratory characterisation and comparative clinical pharmacokinetic data, with no clinically meaningful differences in quality, safety or efficacy.
Why the 'tailored' pathway matters
The EMA's committee adopted a reflection paper on 16 March 2026 setting out when similarity to a reference biologic can be inferred from analytical and pharmacokinetic data rather than from a large comparative efficacy study, the trade publication BioPharm International reported. The paper took the view that such efficacy trials had generally added little decisive information to biosimilarity assessments, meaning most developers are no longer expected to run them.
Shreehas Tambe, Biocon's chief executive and managing director, called the decision "a significant regulatory milestone" for the company. "With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the US, strengthening our global oncology portfolio," he said.
US clearance came two days earlier
The European decision came two days after the US Food and Drug Administration approved the same product, under the name pertuzumab-qcay, on 16 November, BioPharm International reported. It added that Biocon has a global settlement and licence agreement with Genentech under which the earliest licensed US launch is set for the third quarter of 2028.
Biocon has not said when it will launch Pebrilzo in Europe.
The patient population
Citing 2024 estimates from the European Cancer Information System, the company said breast cancer is the most commonly diagnosed cancer among women in Europe. Roughly 15 to 20 per cent of invasive breast cancers show HER2 over-expression or gene amplification, the group of patients for whom pertuzumab-based treatment is used.
Biocon said its cancer portfolio covers solid tumours such as breast cancer, supportive care for chemotherapy-induced neutropenia, and bone health, including osteoporosis and treatment-related bone loss.
What to watch
The next markers will be Biocon's European launch schedule and pricing, and whether other biosimilar makers move quickly to use the EMA's streamlined route for their own products.




